Related Experiment Video
Updated: Jul 14, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
Published on: January 16, 2015
Role of the polycomb repressive complex 2 in acute promyelocytic leukemia
Raffaella Villa1, Diego Pasini, Arantxa Gutierrez
1Centre de Regulacio Genomica, c/ Dr. Aiguader 88, 08003 Barcelona, Spain.
Abstract:
Epigenetic changes are common alterations in cancer cells. Here, we have investigated the role of Polycomb group proteins in the establishment and maintenance of the aberrant silencing of tumor suppressor genes during transformation induced by the leukemia-associated PML-RARalpha fusion protein. We show that in leukemic cells knockdown of SUZ12, a key component of Polycomb repressive complex 2 (PRC2), reverts not only histone modification but also induces DNA demethylation of PML-RARalpha target genes. This results in promoter reactivation and granulocytic differentiation. Importantly, the epigenetic alterations caused by PML-RARalpha can be reverted by retinoic acid treatment of primary blasts from leukemic patients. Our results demonstrate that the direct targeting of Polycomb group proteins by an oncogene plays a key role during carcinogenesis.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Differentiation of Common Myeloid Progenitor Cells
Anaphase Promoting Complex
Anaphase Promoting Complex
RNA Polymerase II Accessory Proteins
Epigenetic Regulation

